The trans-membrane domain of Bcl-2α, but not its hydrophobic cleft, is a critical determinant for efficient IP3 receptor inhibition
Related Experiment Video
Updated: Mar 16, 2026
Examining BCL-2 Family Function with Large Unilamellar Vesicles
Published on: October 5, 2012
Hristina Ivanova1, Abigael Ritaine2, Larry Wagner3
1Katholieke Universiteit Leuven, Laboratory of Molecular and Cellular Signaling, Department of Cellular and Molecular Medicine and Leuven Cancer Institute (LKI), BE-3000 Leuven, Belgium.
Abstract:
The anti-apoptotic Bcl-2 protein is emerging as an efficient inhibitor of IP3R function, contributing to its oncogenic properties. Yet, the underlying molecular mechanisms remain not fully understood. Using mutations or pharmacological inhibition to antagonize Bcl-2's hydrophobic cleft, we excluded this functional domain as responsible for Bcl-2-mediated IP3Rs inhibition. In contrast, the deletion of the C-terminus, containing the trans-membrane domain, which is only present in Bcl-2α, but not in Bcl-2β, led to impaired inhibition of IP3R-mediated Ca2+ release and staurosporine-induced apoptosis. Strikingly, the trans-membrane domain was sufficient for IP3R binding and inhibition. We therefore propose a novel model, in which the Bcl-2's C-terminus serves as a functional anchor, which beyond mere ER-membrane targeting, underlies efficient IP3R inhibition by (i) positioning the BH4 domain in the close proximity of its binding site on IP3R, thus facilitating their interaction; (ii) inhibiting IP3R-channel openings through a direct interaction with the C-terminal region of the channel downstream of the channel-pore. Finally, since the hydrophobic cleft of Bcl-2 was not involved in IP3R suppression, our findings indicate that ABT-199 does not interfere with IP3R regulation by Bcl-2 and its mechanism of action as a cell-death therapeutic in cancer cells likely does not involve Ca2+ signaling.
Insights
The Bcl-2 protein inhibits IP3R function, promoting cancer. Its C-terminus, not the hydrophobic cleft, is crucial for this inhibition, impacting calcium release and apoptosis.
Area of Science:
- Molecular Biology
- Cell Biology
- Cancer Research
Background:
- The anti-apoptotic Bcl-2 protein is implicated in cancer via inhibition of inositol trisphosphate receptors (IP3Rs).
- The precise molecular mechanisms by which Bcl-2 inhibits IP3R function remain incompletely elucidated.
Purpose of the Study:
- To investigate the molecular mechanisms underlying Bcl-2's inhibition of IP3R function and its role in apoptosis.
- To determine the specific domains of Bcl-2 responsible for IP3R interaction and inhibition.
Main Methods:
- Utilized site-directed mutagenesis to disrupt Bcl-2's hydrophobic cleft.
- Generated Bcl-2 C-terminal deletion mutants, including those lacking the transmembrane domain.
- Assessed IP3R-mediated calcium (Ca2+) release and staurosporine-induced apoptosis.
Main Results:
- Disruption of Bcl-2's hydrophobic cleft did not impair IP3R inhibition.
- Deletion of the C-terminus, specifically the transmembrane domain of Bcl-2α, significantly reduced IP3R inhibition and apoptosis.
- The transmembrane domain alone was sufficient for binding and inhibiting IP3Rs.
Conclusions:
- Propose a novel model where the Bcl-2 C-terminus acts as a functional anchor, facilitating IP3R inhibition by positioning the BH4 domain and directly interacting with the IP3R C-terminus.
- Bcl-2's hydrophobic cleft is not involved in IP3R suppression.
- The cancer therapeutic ABT-199 likely does not affect Bcl-2's regulation of IP3R and calcium signaling.
Related Concept Videos
01:11IP3/DAG Signaling Pathway
01:31The Intrinsic Apoptotic Pathway
01:20The JAK-STAT Signaling Pathway
01:42Phosphoinositides and PIPs
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
01:22Amplifying Signals via Enzymatic Cascade
01:16Calmodulin-dependent Signaling
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...